Validation of the NCCN-IPI and the GELTAMO-IPI for diffuse large B-Cell lymphoma treated with R-CHOP in a large cohort of patients from a single institution

Abstract

The discriminative power of International Prognostic Index (IPI) in diffuse large B-cell lymphoma (DLBCL) decreased with the addition of rituximab to chemotherapy. The National Comprehensive Cancer Network (NCCN)-IPI and the Grupo Español de Linfomas y Trasplante Autólogo de Médula Ósea (GELTAMO)-IPI were developed to improve the risk prediction for DLBCL patients. We aim to validate the NCCN-IPI and GELTAMO-IPI in a large and homogeneous cohort of 337 DLBCL patients treated with curative intent with R-CHOP/R-CHOP-like immunochemotherapy. The IPI stratifies patients in two independent risk groups and the estimated 5-year overall survival (OS) of the high-risk (HR) group was 43%. NCCN-IPI discriminated four risk groups and GELTAMO-IPI three risk groups of patients. The predicted 5-year OS of the HR group was 38% and 29%, respectively. NCCN-IPI and GELTAMO-IPI are more accurate prognostic indices than IPI in DBLCL patients treated with immunochemotherapy. GELTAMO-IPI demonstrated enhanced discrimination than NCCN-IPI for the higher-risk population.

Keyword:

• Diffuse large B-cell lymphoma
• NCCN-IPI
• GELTAMO-IPI
• IPI
• pronostic factor

Acknowledgements

E.G.B and Q.S were responsible for study design, data analysis and interpretation and wrote the manuscript. E.G.B. supervised and provided valuable input into the present study. Q.S collected the data. E.G.B, Q.S and M.E analyzed data. S.M., E.D.D., A.C.O., F.C., M.A-C, A.F.S., A.S, E.G.B. provided patients under approved institutional review boards. All authors read, reviewed and approved the final manuscript.

Disclosure statement

The authors have declared no relevant conflicts of interest.

Data sharing statement

For original data, please contact corresponding author.